ADHD

Study: ADHD Patients Benefited From Medical Cannabis
Cannabis May Offer Relief For Adults With ADHD And Improve Quality Of Life: Study
ADHD Relief With Cannabis Products? UK Study Reveals Impact, Benefits And Adverse Events
Cannabis May Offer Relief For Adults With ADHD And Improve Quality Of Life: Study
ADHD Relief With Cannabis Products? UK Study Reveals Impact, Benefits And Adverse Events
Sam Bankman-Fried Appeals For ADHD Medication During Fraud Trial To 'Meaningfully Participate' In Defense
Peru's Coca Leaf Will Be Used For Research Toward Treating ADHD, Learn The Details

ADHD Recent News

How To Enroll In A Psychedelic Clinical Trial In 5 Easy Steps
This article was originally published on Psychedelic Spotlight and appears here with permission. If you fail to meet even one of the inclusion criteria, or you meet even one of the exclusion criteria, then you are not eligible and you will not be selected for participation.
Chamath Palihapitiya Announces SPAC Deal For Akili: Revolutionary Digital Therapy For Mental Illness
A biotech focused SPAC launched by frequent SPAC sponsor Chamath Palihapitiya announced a merger deal Wednesday morning.
MindMed Advances Phase 2a LSD Microdose Trial For Adult ADHD
Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Friday the initiation of Phase 2a proof-of-concept trial of LSD (lysergic acid diethylamide) in adult patients with attention deficit hyperactivity disorder.
ADHD Drug Developer Cingulate Plans NASDAQ Debut
KemPharm Shares Trade Higher After FDA Approval For Azstarys In ADHD
Why Supernus Shares Rallied 24% After-Hours On Tuesday
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) announced Monday that its SPN-812 — a commercial treatment for patients with Attention Deficit Hyperactivity Disorder (ADHD), exhibited positive topline results in late-stage trials.
Digital Therapeutics Field Is Fast On The Rise, Ehave Is Advancing Research In Psychedelics And ADHD Therapy
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Ehave, Inc. (OTCMKTS:EHVVF) is a provider of digital therapeutics, delivering evidence-based therapeutic interventions to patients. 
Sponsored
Video: Using Cannabis To Treat ADD/ADHD, Replacing Adderall And Ritalin
KemPharm's ADHD Candidate Meets Efficacy, Safety Trial Endpoints
What Kids Don't Want Their Parents To Know About Fidget Spinners
KemPharm CEO On Recent Results, Catalysts And Prospects: 'ADHD Is By Far The Larger Market Opportunity'
Alcobra Shares Initiated At Buy; Cantor Sees 'Greater Opportunity For Success'
Shire Just Took Another Step Forward With Its ADHD Drug